Form 8-K

8-K — Allarity Therapeutics, Inc.

Accession: 0001213900-26-090183

Filed: 2026-08-14

Period: 2026-08-14

CIK: 0001860657

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0302157-8k_allarity.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED JUNE 30, 2026 (ea030215701ex99-1.htm)

GRAPHIC (ea030215701_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0302157-8k_allarity.htm · Sequence: 1

false

0001860657

2026-08-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 14, 2026

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41160

87-2147982

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

(401) 426-4664

(Registrant’s telephone number, including

area code)

Not applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

ALLR

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results

of Operations and Financial Condition.

On August 14, 2026, Allarity

Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter

ended June 30, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information contained

in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended

(the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the

Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release, dated August 14, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Allarity Therapeutics, Inc.

Dated: August 14, 2026

By:

/s/ Thomas H. Jensen

Thomas H. Jensen

Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED JUNE 30, 2026

EX-99.1

Filename: ea030215701ex99-1.htm · Sequence: 2

Exhibit 99.1

Allarity Therapeutics Reports Second

Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

- Completed quarter with $26.9 million

in cash and restricted cash

- Key U.S. patent was awarded, protecting

exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042

- AACR 2026 data linked higher stenoparib

DRP® scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP®-guided patient

selection

- Obtained CLIA certification for

its in-house laboratory, enabling full control of DRP® testing to accelerate and support U.S. clinical trials

TARPON SPRINGS, Fla., AUGUST 14, 2026

– Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage

pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30,

2026.

“The second quarter was a highly productive period for Allarity.

During the quarter, the USPTO granted the key U.S. patent covering our stenoparib-specific DRP® companion diagnostic, providing exclusivity

to develop stenoparib with its DRP® into April 2042. This establishes a critical, long-term intellectual property foundation for stenoparib

development and commercialization and reinforces our confidence in the long-term potential of our approach to pairing anticancer therapeutics

with drug-specific companion diagnostics,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics.

“Subsequent to quarter-end, we also successfully completed our

manufacturing campaign for stenoparib, securing drug supply in accordance with the more stringent standards required for late-stage clinical

development. Completion of this campaign represents an important step as we prepare for a pivotal, registrational trial. We have also

secured CLIA certification for our in-house laboratory, enabling us to do all of the necessary testing for the DRP® in-house, which

will further secure our ability to control and accelerate the advance of stenoparib toward FDA approval. I am particularly proud of these

accomplishments as they position the company to drive stenoparib forward as rapidly as possible. Together with the presentation of our

promising, durable Phase 2 clinical benefit data in advanced ovarian cancer patients at leading international oncology conferences, these

achievements further strengthen the foundation for accelerating stenoparib toward FDA approval. Finally, I am pleased that we ended the

quarter with almost $27 million in cash and restricted cash, providing us with the financial resources to continue the important work

of advancing stenoparib.”

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon

Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 1 of 8

Clinical and Drug Development Progress

● Phase

3 manufacturing campaign milestone: During the second quarter, Allarity announced that its active pharmaceutical ingredient (API)

manufacturing campaign for stenoparib was progressing in line with the planned timeline at its world-class contract development and manufacturing

organization (CDMO). Subsequent to quarter-end, the campaign was successfully completed (July 2026), ahead of the originally planned

completion by the third quarter of 2026. The campaign supports accelerating stenoparib toward FDA approval following its FDA Fast Track

designation and was completed in anticipation of the generation of clinical benefit data from the ongoing Phase 2 trial in advanced ovarian

cancer. All manufacturing-related payments were completed during the second quarter and are recorded as prepaid expenses, and no additional

cash outlays for API manufacturing are anticipated.

● Key

U.S. patent granted for the stenoparib DRP® companion diagnostic: The United States Patent and Trademark Office (USPTO) granted

the key U.S. patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic,

with a term extending into April 2042. The grant follows the USPTO’s Notice of Allowance announced in April 2026. The patent covers

methods for predicting clinical benefit from stenoparib based on gene-expression profiles derived from tumor samples, as well as methods

for selecting patients most likely to benefit from stenoparib treatment, and affords commercial exclusivity protection for stenoparib

when used in concert with the stenoparib DRP®.

● AACR

2026 data linking DRP® to enhanced overall survival in ovarian cancer: At the American Association for Cancer Research Annual

Meeting 2026 (AACR 2026), Allarity presented Phase 2 clinical data showing extended overall survival benefit in advanced, platinum-resistant

and refractory ovarian cancer patients, particularly in those patients whose tumors have the highest stenoparib DRP® scores. These

data reinforce the value of leveraging the DRP-based patient selection strategies to select patients most likely to benefit from stenoparib

and to accelerate stenoparib’s advance to FDA approval.

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon

Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 2 of 8

● AACR

2026 data highlighting stenoparib’s potential in colorectal cancer: In a second AACR 2026 poster, the Company presented new

findings demonstrating stenoparib’s mechanism of action—modulating the WNT/β-catenin signaling pathway and inhibiting

the growth of human colorectal cancer cell lines at clinically relevant concentrations. The majority of colorectal cancers activate the

WNT pathway, enabling cancer progression and metastatic spread. Accordingly, inhibition of the WNT pathway may provide an exciting new

therapeutic option for colon and rectal cancers, which remain among the most prevalent and deadly cancers in the United States.

● Poster

presented at ESMO Gynaecological Cancers Congress: Allarity presented a Trial-in-Progress poster outlining the scientific background,

study design, and clinical rationale for its ongoing Phase 2 trial evaluating stenoparib in patients with advanced platinum-resistant

or platinum-ineligible ovarian cancer. The poster was presented by the study’s Principal Investigator, Kathleen N. Moore, M.D.,

an internationally recognized specialist in gynecologic oncology and a leading expert in advanced platinum-resistant and platinum-refractory

ovarian cancer.

● Ovarian

cancer program continued under FDA Fast Track designation: Allarity continued enrollment in its Phase 2 clinical trial protocol evaluating

stenoparib in advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. The amended protocol is designed expressly

to capitalize on the emerging clinical experience with stenoparib in platinum-resistant patients and to accelerate the clinical development

of stenoparib toward FDA approval.

● SCLC

combination trial continued enrollment: The Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small

cell lung cancer (SCLC)—fully funded by the U.S. Department of Veterans Affairs (VA)—continued enrolling patients across

multiple VA medical centers throughout the United States.

● CLIA

certification obtained: Allarity obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA)

for its in-house laboratory in Hørsholm, Denmark. The FDA requires that biomarker testing used to select patients for registration

trials be performed in a CLIA-certified laboratory environment. For the first time, Allarity is now able to perform its DRP® testing

in-house in a CLIA-certified environment to support U.S. clinical trials, including a registrational trial of stenoparib in advanced

ovarian cancer. This is expected to reduce reliance on external laboratories, may shorten turnaround times and reduce costs. It also

may position the Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified laboratory partner in Northern Europe for other

companies seeking to conduct clinical trials in, or commercialize products for the U.S. market.

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon

Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 3 of 8

Corporate

and Strategic Developments

● Scientific visibility at Precision Medicine Forum Europe 2026: CEO

Thomas Jensen presented at Precision Medicine Forum Europe 2026 in Stockholm, Sweden, discussing stenoparib’s dual mechanism of

action and Allarity’s predictive biomarker, as well as the Company’s ongoing Phase 2 trials.

Second Quarter 2026 Financial Review

Results of Operations for the Three Months Ended June 30, 2026

● Cash

Position: As of June 30, 2026, cash and restricted cash totaled $26.9 million, compared to $14.7 million as of June 30, 2025. The

Company used $2.6 million of cash in operating activities during the quarter.

● R&D

Expenses: Research and development (R&D) expenses were $1.3 million for the quarter ended June 30, 2026, compared to $2.3 million

for the quarter ended June 30, 2025.

● G&A

Expenses: General and administrative (G&A) expenses were $1.3 million for the quarter ended June 30, 2026, compared to $1.8 million

for the quarter ended June 30, 2025.

● Total

Comprehensive Loss: The total comprehensive loss attributable to common stockholders was $3.7 million for the quarter ended June

30, 2026, compared to $4.2 million for the quarter ended June 30, 2025. For the six months ended June 30, 2026, the loss was $6.5 million,

compared to $7.2 million for the six months ended June 30, 2025.

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon

Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 4 of 8

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule

dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic

targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has

been implicated in the development and progression of numerous cancers, especially drug-resistant cancers. By inhibiting PARP and blocking

WNT pathway activation, stenoparib’s therapeutic action shows potential as a promising therapeutic for many cancer types, including

ovarian cancer, small cell lung cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization

of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has

completed its first Phase 2 trial for stenoparib in advanced ovarian cancer patients. That trial showed promising and durable clinical

benefit in ovarian cancer patients who had two or more lines of prior lines of therapy and recieved stenoparib twice daily. The updated

data from this study were presented at the AACR special conference on advances in ovarian cancer in September 2025. These analyses are

subject to change as follow-up matures. A new protocol was designed expressly to capitalize on this emerging clinical experience with

stenoparib in platinum-resistant patients and began enrolling patients in the summer of 2025. This amended protocol enrolls only platinum-

resistant or platinum-ineligible patients and is designed to accelerate the clinical development of stenoparib toward FDA approval. In

parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC)

began enrolling patients in early 2026 and is currently enrolling patients across multiple VA sites in the U.S.

About the Drug Response Predictor –

DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® to select those patients who,

by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients

before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may

be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information

from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression

profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical

outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform,

which Allarity believes may be useful in all cancer types and is patented for dozens of anticancer drugs, has been extensively published

in the peer-reviewed literature.

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon

Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 5 of 8

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical

company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase

inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select

those patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in

Denmark and its U.S. business address is in Florida. The Company is committed to addressing significant unmet medical needs in cancer

treatment. For more information, visit www.allarity.com.

Follow Allarity on Social Media

LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements

This press release contains “forward-looking statements”

within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current

expectations or forecasts of future events. The words “anticipate,” “believe,” “continue,” “could,”

“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,”

“potential,” “predicts,” “project,” “should,” “would” and similar expressions

may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking

statements include, but are not limited to, statements regarding the Company’s ongoing and planned clinical development of stenoparib;

the enrollment, conduct, timing and potential results of its Phase 2 trials in advanced ovarian cancer and relapsed small cell lung cancer;

the potential safety, efficacy, tolerability and clinical benefit of stenoparib; the potential use of the stenoparib DRP® companion

diagnostic for patient selection; the advancement of stenoparib toward pivotal development, FDA approval and commercialization; the availability

of drug supply from the completed manufacturing campaign; the anticipated benefits of the Company’s CLIA-certified laboratory; the

potential commercial use of the DRP® platform and laboratory services; the scope and duration of patent protection for stenoparib

and the stenoparib DRP® companion diagnostic; and the Company’s anticipated cash runway and ability to fund its operations and

development plans. Any forward-looking statements in this press release are based on management’s current expectations of future

events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in

or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to clinical

development, patient enrollment, trial execution and regulatory review; the possibility that clinical results may not demonstrate the

anticipated safety, efficacy, durability or clinical benefit of stenoparib; the predictive accuracy, validation, regulatory acceptance

and clinical utility of the stenoparib DRP® companion diagnostic; the Company’s ability to obtain, maintain and enforce intellectual

property protection; the quality, availability and regulatory compliance of stenoparib drug supply; the Company’s ability to maintain

its CLIA certification and other required laboratory approvals; the possibility that anticipated efficiencies, cost savings or commercial

opportunities may not be realized; reliance on third-party clinical sites, investigators, manufacturers and suppliers; and the Company’s

ability to maintain sufficient financial resources and obtain additional funding, if required. For a discussion of other risks and uncertainties,

and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements,

see the section entitled “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission

(the “SEC”) on March 30, 2026, available at the SEC’s website at www.sec.gov, as well as discussions of potential risks,

uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release

is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

###

Company Contact:

investorrelations@allarity.com

Media

Contact:

Thomas Pedersen

Carrotize PR & Communications

+45 6062 9390

tsp@carrotize.com

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon

Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 6 of 8

ALLARITY THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for share and per share data)

June 30,

December 31,

2026

2025

(Unaudited)

ASSETS

Current assets

Cash

$ 16,982

$ 14,687

Restricted Cash

9,999

—

Other current assets

265

Prepaid expenses

3,377

2,110

Tax credit receivable

1,310

866

Total current assets

31,729

17,928

Non-current assets:

Property, plant and equipment, net

386

330

Total assets

$ 32,115

$ 18,258

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities

Accounts payable

$ 4,113

$ 4,282

Accrued expenses and other current liabilities

1,971

2,667

Income taxes payable

Promissory note - short term, net of discounts

20,862

—

Derivative liability

128

Convertible promissory notes and accrued interest

1,424

1,400

Total current liabilities

28,579

8,430

Total liabilities

28,579

8,430

Commitments and contingencies (Note 8)

Stockholders’ equity

Common stock, $0.0001 par value (250,000,000 shares authorized); 19,124,363 and 19,030,619 shares issued and 15,910,724 and 16,080,980 outstanding at June 30, 2026 and December 31, 2025, respectively

Additional paid-in capital

144,683

144,233

Accumulated other comprehensive loss

(1,346 )

(1,021 )

Accumulated deficit

(136,352 )

(130,197 )

Treasury stock, at cost; 3,213,639 and 2,949,639 shares at June 30, 2026, and December 31, 2025, respectively

(3,452 )

(3,190 )

Total stockholders’ equity

3,536

9,828

Total liabilities and stockholders’ equity

$ 32,115

$ 18,258

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon

Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 7 of 8

ALLARITY THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS

(UNAUDITED)

(in thousands, except for share and per share data)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Revenue:

License Revenue

$ —

$ 25

$ —

Total revenue

—

Operating expenses:

Research and development

1,345

2,321

$ 2,642

$ 3,724

General and administrative

1,326

1,812

2,742

3,445

Total operating expenses

2,671

4,133

5,384

7,169

Loss from operations

(2,671 )

(4,133 )

(5,359 )

(7,169 )

Other income (expense):

Interest income

217

237

380

459

Interest expense

(719 )

(12 )

(948 )

(69 )

Foreign exchange gains (losses)

(104 )

1,588

(100 )

1,726

Change in fair value of derivative and warrant liabilities

(128 )

—

(128 )

Total other income (expense), net

(734 )

1,813

(796 )

2,117

Net loss

$ (3,405 )

$ (2,320 )

$ (6,155 )

$ (5,052 )

Net loss per common share, basic and diluted

$ (0.21 )

$ (0.15 )

$ (0.39 )

$ (0.38 )

Weighted average common shares outstanding, basic and diluted

15,910,724

15,543,321

15,944,946

13,357,266

Other comprehensive loss

Net loss

$ (3,405 )

$ (2,320 )

$ (6,155 )

$ (5,052 )

Change in cumulative translation adjustment

(267 )

(1,830 )

(325 )

(2,106 )

Total comprehensive loss

$ (3,672 )

$ (4,150 )

$ (6,480 )

$ (7,158 )

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon

Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 8 of 8

GRAPHIC

Filename: ea030215701_ex99-1img1.jpg · Sequence: 3

Binary file (9204 bytes)

Download ea030215701_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 14, 2026

Entity File Number

001-41160

Entity Registrant Name

ALLARITY THERAPEUTICS, INC.

Entity Central Index Key

0001860657

Entity Tax Identification Number

87-2147982

Entity Incorporation, State or Country Code

Entity Address, Address Line One

123 E Tarpon Ave

Entity Address, City or Town

Tarpon Springs

Entity Address, State or Province

Entity Address, Postal Zip Code

34689

City Area Code

401

Local Phone Number

426-4664

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

ALLR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration